CSIMarket
 


Arca Biopharma Inc   (ABIO)
Other Ticker:  
 

Arca Biopharma Inc 's Working Capital Ratio

ABIO's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Current Liabilities decreased faster than Arca Biopharma Inc 's Current Assets, this led to improvement in Arca Biopharma Inc 's Working Capital Ratio to 39.21 a new company high.

Within In Vitro & In Vivo Diagnostic Substances industry Arca Biopharma Inc booked the highest Working Capital Ratio than Arca Biopharma Inc in the third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 95, from total ranking in the second quarter 2023 at 172.

Explain Working Capital Ratio
How much in Current Assets ABIO´s has?
What is the value of ABIO´s Current Liabilities?


ABIO Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -48.79 % -42.97 % -53.44 % -67.64 % -47.58 %
Y / Y Current Assets Change -12.7 % -14.48 % -17.49 % -21.54 % -31.24 %
Working Capital Ratio MRQ 39.21 25.44 32.94 37.72 23
ABIO's Total Ranking # 95 # 172 # 145 # 148 # 279
Seq. Current Liabilities Change -38.08 % 26.54 % 11.84 % -41.56 % -31.04 %
Seq. Current Assets Change -4.57 % -2.27 % -2.33 % -4.15 % -6.52 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 1
Healthcare Sector # 11
Overall Market # 95


Working Capital Ratio Statistics
High Average Low
39.21 15.73 4.82
(Sep 30 2023)   (Mar 31 2013)




Financial Statements
Arca Biopharma Inc 's Current Liabilities $ 1 Millions Visit ABIO's Balance sheet
Arca Biopharma Inc 's Current Assets $ 39 Millions Visit ABIO's Balance sheet
Source of ABIO's Sales Visit ABIO's Sales by Geography


Cumulative Arca Biopharma Inc 's Working Capital Ratio

ABIO's Working Capital Ratio for the trailling 12 Months

ABIO Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -48.79 % -42.97 % -53.44 % -67.64 % -47.58 %
Y / Y Current Assets TTM Growth -12.7 % -14.48 % -17.49 % -21.54 % -31.24 %
Working Capital Ratio TTM 32.86 28.58 24.72 21.57 17.98
Total Ranking TTM # 3624 # 3459 # 801 # 12 # 3729
Seq. Current Liabilities TTM Growth -38.08 % 26.54 % 11.84 % -41.56 % -31.04 %
Seq. Current Assets TTM Growth -4.57 % -2.27 % -2.33 % -4.15 % -6.52 %


On the trailing twelve months basis Current Liabilities decreased faster than Arca Biopharma Inc 's average Current Assets, this led to increase in in Arca Biopharma Inc 's Working Capital Ratio to 32.86, above ABIO average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher Working Capital Ratio than Arca Biopharma Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3459 to 3624.

Explain Working Capital Ratio
How much in Current Assets ABIO´s has?
What is the value of ABIO´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 17
Healthcare Sector # 977
Within the Market # 3624


trailing twelve months Working Capital Ratio Statistics
High Average Low
32.86 14.31 6.56
(Sep 30 2023)   (Mar 31 2018)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within In Vitro & In Vivo Diagnostic Substances Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Arca Biopharma Inc   39.21 $ 38.892  Millions$ 0.992  Millions
Intellia Therapeutics Inc   9.72 $ 893.493  Millions$ 91.953  Millions
Celldex Therapeutics inc   8.84 $ 245.933  Millions$ 27.836  Millions

Date modified: 2023-10-19T20:31:31+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com